Ketek: Halt Is Urged for Trials of Antibiotic in Children - How does one justify balancing the risk of fatal liver failure against one day less of ear pain?

[Guest guest]

June 8, 2006

*Halt Is Urged for Trials of Antibiotic in Children*

By GARDINER HARRIS

http://www.nytimes.com/2006/06/08/science/08drug.html

A Food and Drug Administration official called in May for a drug company

to halt clinical trials of an antibiotic in children because the drug

could be deadly, according to internal memorandums sent to other F.D.A.

officials.

The drug, Ketek, made by Sanofi-Aventis, is being tested as a treatment

for ear infections and tonsillitis in nearly 4,000 infants and children

in more than a dozen countries, including the United States, according

to postings on a government Web site. But Ketek, which is currently

approved for use only in adults, has been reported to cause liver

failure, blurred vision and loss of consciousness in adults.

" How does one justify balancing the risk of fatal liver failure against

one day less of ear pain? " Dr. Rosemary Johann-Liang, an official in the

Office of Drug Safety at the agency, wrote in one of the memorandums, a

copy of which was obtained by The New York Times.

Sanofi-Aventis is sponsoring four clinical trials in children ages 6

months to 13 years, according the Web site posting. The drug agency

approved plans for the trials.

There is growing evidence that Ketek is unusually toxic, according to a

recent review by F.D.A. safety officials. Twelve adult patients in the

United States have suffered liver failure, including four who died; 23

others suffered serious liver injury.

The safety officials wrote in their review that the agency should

consider forcing Sanofi-Aventis to withdraw Ketek from the market,

severely restrict its uses, even in adults, or add a prominent warning

to its label about potentially fatal side effects.

More than five million prescriptions for Ketek have been written in the

United States since its approval two years ago.

Asked about the memorandum written by Dr. Johann-Liang, an F.D.A.

spokeswoman, Bro, said that it was " a preliminary, raw assessment "

and that " the final decision will be made by experts who have the full

benefit of a large section of opinion and scientific fact. "

Feltmann, a spokeswoman for Sanofi-Aventis, said in an e-mail

message, " We are engaged in ongoing discussions with the F.D.A.

regarding Ketek. "

Other antibiotics cause liver failure, but Ketek seems to do so almost

four times as often, the safety officials concluded in the review.

Ketek can also cause blurred vision and loss of consciousness, problems

that are unique to it. In her memorandum, Dr. Johann-Liang asked how

Sanofi-Aventis's investigators were going to assess whether infants were

suffering blurred vision.

" If we cannot monitor for this event in infants/young children

appropriately in the clinical trial setting, what can we conclude from

the safety results of the trial? " she asked.

Dr. Danny , an infectious-disease specialist at Duke University

who was consulted separately by the drug agency, concluded that the

pediatric trials with Ketek were a cause for concern and " hard to

support, " according to the memorandums obtained by The New York Times.

Dr. did not respond to voice-mail or e-mail messages left for

him yesterday.

In his memorandum, Dr. said that in up to 87 percent of cases,

pediatric ear infections resolved within a few days without treatment.

Tests of an unusually risky antibiotic in infants with ear infections

might be justified if the infants had already been treated

unsuccessfully with safer antibiotics first, he wrote.

Sanofi-Aventis planned to give Ketek as a first-line therapy, according

to the company's trial descriptions.

The drug agency's actions in regard to Ketek are being investigated by

Senator E. Grassley, the Iowa Republican who is chairman of the

Senate Finance Committee, as well as by Representatives J. Markey

of Massachusetts and Henry A. Waxman of California, both Democrats.

Sanofi-Aventis first asked the agency to approve the drug in February

2000. But officials demurred, citing reports of side effects. So the

company undertook a study of Ketek in 24,000 patients to prove its

safety. The trial was marred by fraud. One of the investigators on the

study is now in federal prison; another lost his medical license.

The F.D.A. said it dismissed the study's results and instead asked the

company to report its experience with Ketek in Europe, where it was

approved in 2001. Although it is unusual for the agency to approve a

drug based upon its use elsewhere, in April 2004, it . did just that,

approving Ketek to treat sinusitis, bronchitis and pneumonia.

Since then, problems with the drug have continued to mount. By April,

the agency had reports of 110 cases of liver problems associated with

Ketek, most of which occurred in otherwise healthy people, according to

the safety review. In one, a 49-year-old woman took no more than two

doses of the drug before becoming nauseous and vomiting. She was

hospitalized five days later and died.

Since they are submitted voluntarily, these kinds of case reports

usually represent only a small fraction -- estimates range from 1

percent to 10 percent -- of actual drug problems. The reports that the

F.D.A. has received so far are unusual because of their " rapid tempo and

severity, " the agency's internal safety report said.

The agency officials estimated that Ketek caused acute liver failure in

23 people for every 10 million prescriptions, about four times the rate

of such events seen in other antibiotics.

In 1999, sales of the antibiotic Trovan were severely restricted after

it was shown to cause liver failure in 58 people for every 10 million

prescriptions.

In her memorandum, Dr. Johann-Liang suggested that Ketek's risks

outweighed its benefits.

She noted that powerful antibiotics known as fluoroquinolones can also

damage the liver. But she said that those drugs were available in

intravenous forms and " are also used for more serious infectious

diseases rather than solely for minor upper respiratory indications, " as

Ketek is.

Dr. Johann-Liang wrote in her memorandum that the parents of patients in

Sanofi-Aventis's pediatric trials must be better informed about Ketek's

risks " in order for any of these trials to continue to proceed. "

She added that the parents " need to know that the 'close monitoring' for

visual events is not possible in very young children, and the long-term

consequences of such adverse reactions are unknown for the developing

system. "

Dr. agreed that the brochure about the trials and

informed-consent material given to parents " must address in plain

language the risks, and severity of risks, of adverse events. "

Copyright 2006 The New York Times Company

The material in this post is distributed without

profit to those who have expressed a prior interest

in receiving the included information for research

and educational purposes. For more information go to:

http://www4.law.cornell.edu/uscode/17/107.html

http://oregon.uoregon.edu/~csundt/documents.htm

If you wish to use copyrighted material from this email

for purposes that go beyond 'fair use', you must obtain

permission from the copyright owner.